Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2010-6-24
pubmed:abstractText
Concomitant chemoradiotherapy (CT/RT) is the standard treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN). We evaluated the efficacy of induction docetaxel (Taxotere), cisplatin, and 5-fluorouracil (TPF) before CT/RT versus CT/RT alone.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1569-8041
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1515-22
pubmed:meshHeading
pubmed-meshheading:20032123-Adult, pubmed-meshheading:20032123-Aged, pubmed-meshheading:20032123-Aged, 80 and over, pubmed-meshheading:20032123-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20032123-Carcinoma, Squamous Cell, pubmed-meshheading:20032123-Cisplatin, pubmed-meshheading:20032123-Combined Modality Therapy, pubmed-meshheading:20032123-Feasibility Studies, pubmed-meshheading:20032123-Female, pubmed-meshheading:20032123-Fluorouracil, pubmed-meshheading:20032123-Head and Neck Neoplasms, pubmed-meshheading:20032123-Humans, pubmed-meshheading:20032123-Male, pubmed-meshheading:20032123-Middle Aged, pubmed-meshheading:20032123-Neoplasm Staging, pubmed-meshheading:20032123-Radiotherapy Dosage, pubmed-meshheading:20032123-Remission Induction, pubmed-meshheading:20032123-Survival Rate, pubmed-meshheading:20032123-Taxoids, pubmed-meshheading:20032123-Treatment Outcome
pubmed:year
2010
pubmed:articleTitle
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
pubmed:affiliation
Department of Medical Oncology, Venezia, Italy. adriano.paccagnella@ulss12.ve.it
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II